Keli Coleman, MD: Predictors of Hospitalization, Return Visits in Children with SCD
December 14th 2023Keli Coleman, MD, discusses findings from her research about the role of pain scores and opioids in predicting hospitalization and return visits in children with sickle cell disease and uncomplicated pain crises.
Study Addresses Menstrual Pain in Sickle Cell Disease, Role of Reproductive Health Specialists
Although more than half of female patients with sickle cell disease reported sickle cell pain associated with their menstrual cycles, only 12.5% had used ≥1 hormonal therapies within the past 3 months.
Hydroxyurea Therapy Shown Not to Impact Onset of Puberty in Male Sickle Cell Disease Patients
This new data on a European sickle cell disease cohort expands upon existing knowledge of the effects of HU on fertility, with the findings showing the benefits of cryopreservation.
Low Arginine Bioavailability Predicts Poor Clinical Outcomes in Sickle Cell Disease
December 9th 2023Two experts describe the correlation between the severity of arginine deficiency and worse clinical outcomes among hospitalized children with sickle cell disease experiencing vaso-occlusive pain episodes.
SUMMIT: Bezuclastinib Demonstrates Reduction in NonAdvSM Symptoms
December 9th 2023Bezuclastinib, a targeted oral therapy, shows promise in reducing disease burden and improving symptoms by 50% or more in nonadvanced systemic mastocytosis patients, as revealed in the phase 2 SUMMIT trial data presented at ASH 2023.
From Early Hypothesis to Clinical Data About Reducing Vaso-Occlusive Episodes with Arginine Therapy
December 22nd 2022Almost 25 years later, Dr. Claudia Morris concluded 2022 by presenting phase 2 data at the 64th ASH Annual Meeting that demonstrated the therapy's benefit, and her original premise. Her team's phase 3 trial evaluating Arg is currently underway.